An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)

類似資料

• A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity
  著者:: Ling, Xiang, 等
  出版事項: (2012)
• cIAP2 supports viability of mice lacking cIAP1 and XIAP
  著者:: Heard, Kristen N, 等
  出版事項: (2015)
• Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
  著者:: Santha, Sreevidya, 等
  出版事項: (2020)
• Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles’ heel of cancer?
  著者:: Li, Fengzhi
  出版事項: (2014)
• Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
  著者:: Gill, Catherine, 等
  出版事項: (2009)